Show simple item record

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation

dc.contributor.authorMikkelsen, Ross B.en_US
dc.contributor.authorContessa, Joseph N.en_US
dc.contributor.authorAbell, Angelaen_US
dc.contributor.authorValerie, Kristofferen_US
dc.contributor.authorSchmidt-Ullrich, Rupert K.en_US
dc.date.accessioned2006-09-11T14:28:47Z
dc.date.available2006-09-11T14:28:47Z
dc.date.issued2006-01en_US
dc.identifier.citationContessa, Joseph N.; Abell, Angela; Mikkelsen, Ross B.; Valerie, Kristoffer; Schmidt-Ullrich, Rupert K.; (2006). "Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation." Breast Cancer Research and Treatment 95(1): 17-27. <http://hdl.handle.net/2027.42/44234>en_US
dc.identifier.issn0167-6806en_US
dc.identifier.issn1573-7217en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/44234
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16267617&dopt=citationen_US
dc.description.abstractEGFR and ErbB2 are two members of the ErbB family of receptor Tyr Kinases identified as therapeutic targets for treating carcinomas. Breast carcinoma cells express different complements and variable proportions of ErbB receptor Tyr kinases, which activate unique and redundant signaling cascades that are essential for cell survival. Previously it was shown that a COOH-terminal truncation mutant of the EGFR (EGFR-CD533) blocks EGFR dependent signals and radiosensitizes breast carcinoma cells. In this study the effects of EGFR-CD533 and an analogous truncation mutant of ErbB2 (ErbB2-CD572) on ErbB receptor family dimerization and signaling are further investigated. Using adenoviral vectors in breast carcinoma cell lines with variable ErbB expression profiles, we demonstrate different effects for each deletion mutant. EGFR-CD533 blocks ligand stimulation of EGFR, ErbB2, and ErbB4, but is associated with a compensatory Tyr kinase activity resulting in phosphorylation of ErbB3. In contrast, ErbB2-CD572 produces a weaker, non-specific pattern of ErbB receptor family inhibition, based upon the ErbB expression pattern of the cell type. Investigation of the compensatory Tyr kinase activity associated with EGFR-CD533 expression identified an ErbB3/c-Src signaling pathway that regulates expression of anti-apoptotic Bcl family proteins. This signaling is active in the T47D cell line, which inherently over-express ErbB3, absent in MDA-MB231 cells, which have low ErbB3 expression levels, and is restored in a MDA-MB231 cell line engineered to over-express ErbB3. Furthermore we demonstrate that ErbB3/c-Src signaling is radio-protective, and that its elimination through pharmacologic inhibition of c-Src enhances radiation-induced apoptosis. In summary, these studies identify a novel ErbB3/c-Src survival signal and point to ErbB3 expression levels as an important variable in therapeutic targeting of ErbB receptors in breast carcinoma cells.en_US
dc.format.extent481362 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Springer Science+Business Media, Inc.en_US
dc.subject.otherApoptosisen_US
dc.subject.otherC-Srcen_US
dc.subject.otherEGFRen_US
dc.subject.otherErbB3/Her3en_US
dc.titleCompensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiationen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelOphthalmologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumThe Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA, ; Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, UH B2 C490, Box 0010, Ann Arbor, MI, 48109, USA, ; Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, UH B2 C490, Box 0010, Ann Arbor, MI, 48109, USA,en_US
dc.contributor.affiliationotherThe Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA,en_US
dc.contributor.affiliationotherThe Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA,en_US
dc.contributor.affiliationotherThe Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA,en_US
dc.contributor.affiliationotherThe Department of Radiation Oncology, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA, 23298, USA,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid16267617en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/44234/1/10549_2005_Article_9023.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s10549-005-9023-9en_US
dc.identifier.sourceBreast Cancer Research and Treatmenten_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.